Journal
STEM CELL RESEARCH & THERAPY
Volume 14, Issue 1, Pages -Publisher
BMC
DOI: 10.1186/s13287-023-03585-0
Keywords
Mesenchymal stromal cells; Stem cells; Tumor tropism; Therapy; Anti-tumorigenic; Pro-tumorigenic
Ask authors/readers for more resources
Mesenchymal stromal cells (MSCs) have shown great promise in various fields such as regenerative medicine and cancer therapy. However, their role as important components within the tumor microenvironment poses potential tumorigenic risks, hindering their clinical translation.
Mesenchymal stromal cells (MSCs) show considerable promise in regenerative medicine with superior anti-fibrotic, immunomodulatory, and angiogenic functions. More recently, discovered with the tumor tropism, MSCs have been exploited as the basis of targeted cancer therapy. In this scenario, MSCs can directly home to tumor tissues and play anti-tumor properties. In addition, MSCs, MSC-derived exosomes and MSC-derived membranes are often developed as carriers for precisely delivering cytotoxic agents to cancer sites, including chemotherapeutic drugs, therapeutic genes, or oncolytic viruses. However, it has revealed the tumorigenic risk of MSCs as an important component within the tumor microenvironment, hampering the translation of MSC-based cancer therapies into clinical settings. Therefore, in this review, we introduce the specific tumor-tropic ability of MSCs and underlying mechanisms. We also summarize the current application of MSC-based therapeutic approaches in treating gynecologic cancers, mainly including cervical, ovarian, and endometrial cancers. Moreover, we discuss the main challenges that the current MSC-based cancer therapies are facing.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available